FDA Emphasizes “Deregulatory” Efforts In Mobile Medical Apps Final Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
In a long-awaited final guidance, FDA affirmed its plan to practice enforcement discretion for most mobile medical apps, except those applications that present the same risks as conventional FDA-regulated devices. Some digital health stakeholders praised the guidance, while others wished FDA had waited.
You may also be interested in...
Pending Mobile Medical Apps Guidance Provokes Heated Controversy
An impassioned debate brewing about FDA’s planned timing for finalizing mobile medical apps guidance bubbled to the surface at a recent meeting of the HHS workgroup tasked with recommending a health IT regulatory framework. Despite pressure to delay the guidance, FDA says it is still pushing ahead.
Workgroup Unveils Preliminary Health IT Regulation Proposals
An HHS-sponsored workgroup issued its initial recommendations for a health IT regulatory framework, featuring risk-based oversight, adverse event reporting and better agency coordination.
FDA Mobile Health Policy Proposal Draws Fire From Far And Wide
A draft guidance meant to clarify FDA’s regulatory policies surrounding mobile medical applications has raised as many questions as it tried to answer.